Brokerages Anticipate Endo International PLC (ENDP) Will Post Earnings of $0.45 Per Share

Wall Street brokerages expect Endo International PLC (NASDAQ:ENDP) (TSE:ENL) to post $0.45 earnings per share (EPS) for the current quarter, Zacks reports. Five analysts have issued estimates for Endo International’s earnings, with the lowest EPS estimate coming in at $0.36 and the highest estimate coming in at $0.66. Endo International posted earnings per share of $0.67 in the same quarter last year, which would indicate a negative year over year growth rate of 32.8%. The business is expected to issue its next earnings results on Tuesday, May 14th.

According to Zacks, analysts expect that Endo International will report full year earnings of $2.24 per share for the current fiscal year, with EPS estimates ranging from $2.05 to $2.81. For the next financial year, analysts forecast that the business will report earnings of $2.39 per share, with EPS estimates ranging from $1.78 to $3.12. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that cover Endo International.

Endo International (NASDAQ:ENDP) (TSE:ENL) last announced its quarterly earnings results on Thursday, February 28th. The company reported $0.75 EPS for the quarter, beating the consensus estimate of $0.59 by $0.16. Endo International had a negative net margin of 35.00% and a negative return on equity of 337.13%. During the same period last year, the company earned $0.77 EPS.



A number of research firms recently commented on ENDP. TheStreet lowered shares of Endo International from a “c-” rating to a “d+” rating in a research note on Tuesday, November 27th. Mizuho lowered their price objective on shares of Endo International to $15.00 and set a “neutral” rating on the stock in a research note on Monday, November 26th. Piper Jaffray Companies restated a “hold” rating on shares of Endo International in a report on Friday, March 1st. Zacks Investment Research cut shares of Endo International from a “hold” rating to a “sell” rating in a report on Wednesday, February 13th. Finally, ValuEngine upgraded shares of Endo International from a “sell” rating to a “hold” rating in a report on Monday, February 4th. Fourteen analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Endo International has an average rating of “Hold” and an average price target of $16.00.

A number of institutional investors have recently bought and sold shares of ENDP. Norges Bank acquired a new position in Endo International in the 4th quarter worth approximately $21,218,000. Panagora Asset Management Inc. boosted its stake in Endo International by 10,718.5% in the 3rd quarter. Panagora Asset Management Inc. now owns 1,775,205 shares of the company’s stock worth $29,877,000 after purchasing an additional 1,758,796 shares during the period. Teachers Advisors LLC boosted its stake in Endo International by 230.1% in the 3rd quarter. Teachers Advisors LLC now owns 1,468,025 shares of the company’s stock worth $24,707,000 after purchasing an additional 1,023,350 shares during the period. Canada Pension Plan Investment Board boosted its stake in Endo International by 143,723.6% in the 4th quarter. Canada Pension Plan Investment Board now owns 730,624 shares of the company’s stock worth $5,333,000 after purchasing an additional 730,116 shares during the period. Finally, Oregon Public Employees Retirement Fund acquired a new position in Endo International in the 4th quarter worth approximately $76,000. 98.25% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ ENDP traded up $0.01 during mid-day trading on Friday, reaching $8.42. 1,488,832 shares of the company traded hands, compared to its average volume of 3,429,484. Endo International has a fifty-two week low of $5.27 and a fifty-two week high of $18.50. The firm has a market capitalization of $1.88 billion, a PE ratio of 2.91 and a beta of 1.21.

Endo International Company Profile

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

See Also: 12b-1 Fees

Get a free copy of the Zacks research report on Endo International (ENDP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.